Navigation Links
Sinus sufferers miss out on work or social activities due to summer allergies
Date:7/31/2008

SANTA ROSA, Calif., July 30, 2008 While summer is the time of year people like to spend most of their day outside, summer allergens keep many sinus sufferers from enjoying activities such as barbequing, hanging out at the pool and spending time in the park, to name a few.

In fact, a new survey of more than 1,000 consumers shows that one-third of sinus sufferers say they miss or cut short social outings or business engagements because of their symptoms. With ragweed season right around the corner, sinus problems will flare for the millions of Americans suffering with seasonal allergies. But, surprisingly, the majority of allergy sufferers (64%) do not do anything to relieve their symptoms, according to the survey. The reason may be that more than two out of five sinus sufferers say their sinus or allergy medication does not work.

However, there is the option of saline nasal wash, which is a physician-recommended, natural technique that relieves sinus symptoms by gently rinsing away allergens and excessive mucus that can lead to irritation and infection. One person who knows how much sinus problems can impact their livelihood and quality of life is Mandy-Rae Cruickshank, a seven time world-record holding freediver, who is also a chronic sinus sufferer.

"I have always struggled with sinus issues, which creates a challenge since I dive nearly everyday. It also affected my social life outside of competitive freediving," says Mandy-Rae. "When I discovered Sinus Rinse, a saline nasal wash in a squeeze bottle, I was amazed by how well it works to relieve my symptoms so I can enjoy my career as well as other outdoor activities."

Saline nasal wash is a clinically proven technique to alleviate allergy and sinus symptoms. A recent study shows more than a 50% reduction in symptoms by users of NeilMed's Sinus Rinse. Additionally, daily saline nasal rinsing improves sinus-related quality of life and decreases medication use such as ant
'/>"/>

Contact: Sarah Smith
ssmith@healthstarpr.com
646-722-8810
HealthStar PR
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
2. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
3. Sinusitis Treatments Found Ineffective
4. 31 Million Americans Suffer From Sinus Infections
5. Balloon catheter-based sinus surgery radiation exposure very low, safe
6. Dont Prescribe Antibiotics for Adult Sinus Woes
7. Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients
8. Potential blood test for chronic sinusitis identified
9. Immune system kick-started in moist nasal lining in sinusitis, asthma and colds
10. The Chopra Center for Wellbeing Introduces Ayurnas: A Soothing Natural Remedy for Sinus Congestion, Chronic Headaches, and Cold Symptoms
11. Meditation May Help Rheumatoid Arthritis Sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4